预约演示

更新于：2025-06-13

Exenatide

艾塞那肽

更新于：2025-06-13

概要

基本信息

药物类型

合成多肽

别名

Exenatide (JAN/USAN/INN)、EXENATIDE SYNTHETIC、Exendin-4

+ [20]

靶点

GLP-1R

作用方式

激动剂

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

Amylin Pharmaceuticals, Inc.

在研机构

Icure Pharmaceutical Inc.Aerami Therapeutics, Inc.

Eli Lilly Nederland BV

+ [3]

非在研机构

Intarcia Therapeutics, Inc.

Eli Lilly & Co.

AstraZeneca PLC

+ [1]

权益机构

沈阳三生制药有限责任公司

Invex Therapeutics Ltd.

Eli Lilly & Co.

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (2005-04-28),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构/序列

Sequence Code 751

来源: *****

关联

354

项与艾塞那肽相关的临床试验

CTIS2024-519014-31-00

/ Recruiting临床1期IIT

- CHDR2418

开始日期2025-03-12

申办/合作机构

Centre for Human Drug Research

NCT02586831

/ Withdrawn临床1/2期IIT

A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes

To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects receiving combinational therapy versus those receiving placebo. The study will also examine the effect of the proposed treatments on immunological outcomes, specifically proportion of regulatory T cells at the 1 year visit.

开始日期2025-01-01

申办/合作机构

University of Miami

[+1]

NCT05663515

/ RecruitingN/A

EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an "intention-to-treat" approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a primary diagnosis of pancreatic cancer during follow-up.

开始日期2024-09-30

申办/合作机构

AstraZeneca PLC

[+1]

100 项与艾塞那肽相关的临床结果

登录后查看更多信息

100 项与艾塞那肽相关的转化医学

登录后查看更多信息

100 项与艾塞那肽相关的专利（医药）

登录后查看更多信息

4,168

项与艾塞那肽相关的文献（医药）

2025-09-01·PHYSIOLOGY & BEHAVIOR

The role of vasopressin deficiency in the fluid intake suppression hyper-responsivity to central glucagon-like peptide-1 in the Brattleboro rat

Article

作者: David, Sydney A ; Paul, Matthew J ; Daniels, Derek ; Brakey, Destiny J

Food and fluid intakes are physiologically and behaviorally intertwined; one often affects the other. Likewise, pharmacological manipulations that influence eating often affect drinking. For example, glucagon-like peptide-1 (GLP-1) suppresses both eating and fluid intake, but the respective elements of the GLP-1 system remain unparsed. The Brattleboro rat has emerged as a model to test for separable elements in the control of fluid or food intake. Brattleboro rats have hereditary hypothalamic vasopressin deficiency. To compensate for the resultant polyuria, they drink copious amounts of water. Eating, however, is similar to that observed in wildtype littermates and other Long Evans rats. Interestingly, treatment with a GLP-1 receptor agonist exendin-4 (Ex4) causes an exaggerated suppression of drinking in Brattleboro rats, but suppression of eating is comparable to wildtype controls. To test if this hyper-responsivity depends on the polydipsia in these rats, we normalized their drinking using desmopressin (ddAVP), a V2R agonist, before treatment with Ex4. ddAVP attenuated, but did not completely prevent, the hyper-responsivity to Ex4. Conversely, we treated wildtype rats with acute or chronic tolvaptan, a V2R antagonist, which generated a Brattleboro-like polydipsia, but this did not recapitulate the hyper-responsivity to Ex4 observed in Brattleboro rats. Based on these results, we conclude that polydipsia alone is insufficient to generate a hyper-responsive fluid intake suppression by Ex4, and that Brattleboro rats have at least some persistent hyper-responsivity to Ex4, even after alleviation of their polydipsia. These results provide important context for future studies using Brattleboro rats to study the GLP-1 system.

2025-08-01·JOURNAL OF AFFECTIVE DISORDERS

A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults

Article

作者: DelBello, Melissa P ; Adler, Caleb M ; Welge, Jeffrey A ; Patino, Luis R ; Blom, Thomas J ; Strawn, Jeffrey R

OBJECTIVE:

To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine.

METHODS:

Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks. Weight and body mass index (BMI) were monitored throughout the study. A secondary objective was to evaluate the tolerability of exenatide and its effects on mood and psychotic symptoms.

RESULTS:

A significant difference in weight change was detected between the treatment groups. Participants in the exenatide group experienced on average a minor weight loss, while participants in the placebo group on average experienced weight gain (-0.5 kg [-0.6 %] vs. +2.6 kg [+2.8 %], both p < .01). The most common side effects in the exenatide group were gastrointestinal symptoms and headaches. There were no clinically meaningful differences between the groups in changes to mood or psychotic symptoms.

CONCLUSIONS:

Exenatide is effective and well-tolerated for attenuating olanzapine-associated weight gain.

CLINICAL TRIAL REGISTRATION INFORMATION:

Exenatide for the Treatment of Weight Gain Associated with Olanzapine in Obese Adults. NCT00845507.

2025-07-01·NEUROPHARMACOLOGY

Exogenous oral application of PYY and exendin-4 impacts upon taste-related behavior and taste perception in wild-type mice

Article

作者: Dotson, Cedrick D ; Iyer, Satya ; Montmayeur, Jean-Pierre ; Zolotukhin, Sergei

Several gut peptides have been implicated in feeding and body mass accumulation. Glucagon-like peptide 1 (GLP-1) and peptide tyrosine-tyrosine (PYY) have been shown to mediate satiety and reduce food intake. While systemic administration of such peptides has been explored as a therapy for metabolic disease, the effects of these hormones on taste signaling should also be considered given the importance of taste to feeding decisions and considering the fact that components of these signaling systems are expressed in cells of the peripheral gustatory system. We previously demonstrated that genetic disruption of PYY signaling in mice can impact on taste responsiveness and feeding and that viral expression of PYY in the salivary glands of PYY knockout mice can rescue responsiveness. The present work uses adeno-associated virus-mediated salivary gland treatment with both GLP-1 receptor agonist exendin-4 and/or PYY encoding vectors to explore the effect of stimulating these orally present signaling systems on taste-related behavioral responsiveness in male wild-type mice with intact peptide signaling systems. Results showed a significant effect of salivary gland treatment on responsiveness to multiple taste qualities. Data gathered from taste bud cells in vitro suggest that these peptides directly influence the responsiveness of these primary sensory cells. Collectively, these findings show that taste perception can be modulated by the exogenous application of satiety peptides in wild-type mice and suggest that the taste bud is a promising substrate for food intake modulation.

353

项与艾塞那肽相关的新闻（医药）

2025-05-31

·药时空

见微知著，一文盘点 GLP-1RA 心血管获益差异

动脉粥样硬化性心血管疾病（ASCVD）是 2 型糖尿病（T2DM）患者重要的伴发疾病，也是其致死和致残的主要原因[1]。据统计，每 3 位糖尿病患者中就有 1 位合并心血管疾病[2]。在我国，每 2 位糖尿病患者就有 1 位死于心脑血管事件[3]。自 2024 年以来，国内外权威指南重磅更新[2,4]，胰高血糖素样肽-1 受体激动剂（GLP-1RA）跃升为 T2DM 合并 ASCVD 患者的一线用药。目前，我国已上市的 GLP-1RA 药物近 10 种，涵盖短效制剂（贝那鲁肽、艾塞那肽、利司那肽），以及长效制剂（利拉鲁肽、艾塞那肽周制剂、洛塞那肽、司美格鲁肽片及注射液、度拉糖肽）[2]。然而，并非所有 GLP-1RA 药物都具备明确的心血管获益。大型心血管结局试验（CVOT）结果显示，GLP-1RA 药物在心血管保护方面并不具备类效应，且不同 GLP-1RA 在心血管保护方面也存在显著差异[5-6]，有的可显著降低全因死亡风险，有的则更侧重于卒中风险的干预。那么，在临床实践中应如何科学选择合适的 GLP-1RA？本文将系统梳理各类 GLP-1RA 的临床研究结果及指南推荐，为合并不同心血管疾病的 T2DM 提供诊疗方案参考。01异质性揭秘：GLP-1RA 的 CVOT 研究数据对比LEADER 研究[7]、REWIND 研究[8]及 SUSTAIN 6 研究[9]结果表明，对于伴有心血管疾病（CVD）或心血管高风险的 T2DM 患者，利拉鲁肽、度拉糖肽、司美格鲁肽（注射剂型）药物均较安慰剂显著降低 3P-MACE（非致死性心肌梗死、非致死卒中或心血管死亡的复合终点）风险，分别降低 13%、12%、26%，见表 1。尽管三种药物均达到了 3P-MACE 终点，但在具体事件获益方面存在差异：利拉鲁肽是目前三者中唯一显著降低心血管死亡风险的药物，度拉糖肽和司美格鲁肽（注射剂型）则无显著差异[7-9]。这一发现尤为关键，因为糖尿病患者的心血管死亡风险为非糖尿病人群的 2.1 倍[10]。我国糖尿病患者中 47.5% 的男性和 49.7% 的女性死于心血管疾病[3]。因此，利拉鲁肽在降低心血管死亡方面的独特优势，具有重要临床指导意义。利拉鲁肽虽在卒中风险方面有一定获益，但未达到统计学显著差异[7]；相比之下，司美格鲁肽降低卒中风险 39%，度拉糖肽降低 24%，司美格鲁肽显示出更强的卒中预防效果[8-9]。因此，2024 年发布的《2 型糖尿病患者卒中预防及血糖管理专家共识》[11]推荐将这两种药物用于卒中一级预防。三种药物在降低心肌梗死风险方面均显示一定获益，但无显著差异。02利拉鲁肽：独特作用机制发挥心血管保护如上所述，不同 GLP-1RA 对于心血管获益存在明显差异。其中，利拉鲁肽不仅可显著降低心血管死亡，还能减少非致死性心梗和卒中风险[7]。其显著的心血管保护效应，源于其独特的药理机制。研究显示，利拉鲁肽可通过直接与间接机制，协同发挥作用，为 T2DM 患者的心血管健康提供全方位支持[12-13]。图 1. 利拉鲁肽分别降低三个单独成分事件的风险JACC（IF = 12.9）改善心肌灌注，提高能量代谢T2DM 患者的心脏损伤与心肌血流减少和能量代谢异常密切相关[13]。2024 年发表于 JACC（IF = 12.9）的一项临床研究显示[13]，利拉鲁肽可通过减轻内皮细胞的内质网功能障碍以及恢复血管胰岛素敏感性，来改善 T2DM 患者的心肌灌注。研究结果显示，对于 T2DM 患者来说，与单纯减少胰岛素抵抗（IR）治疗策略相比（吡格列酮治疗），利拉鲁肽可显著增加应激心肌血流（1.62～2.08 mL/g/min，P = 0.01）和心肌灌注储备（2.40～2.90，P = 0.01），同时显著提高静息和负荷情况下心肌的磷酸肌酸与三磷酸腺苷浓度（PCr/ATP）比值（P < 0.01）及 6 分钟步行距离（488～521 m，P = 0.009）。以上提示利拉鲁肽在改善 T2DM 患者心肌功能，改善心肌灌注、能量代谢和运动耐量方面有显著效果。图 2. 利拉鲁肽 vs 吡格列酮引起的心肌变化注：A. 负荷心肌血流、B. 心肌灌注储备、C. 静息 PCr/ATP、D. 负荷 PCr/ATP减缓动脉粥样硬化与冠心病进展糖尿病患者因血液黏滞度增加，属于冠心病的高发人群，而利拉鲁肽在降低 2 型糖尿病患者血糖的同时，可改善心功能、免疫因子水平及血管微环境[12]。它能提高血管内皮生长因子（VEGF）和基质细胞衍生因子-1α（SDF-1α）的循环浓度，促进血管修复，减缓动脉粥样硬化进程[13]。此外，利拉鲁肽还可通过降低血糖、调节血脂代谢，进一步改善动脉粥样硬化[12]。改善急性心梗后心脏重构当 T2DM 患者发生心肌梗死后，在直接经皮冠状动脉介入治疗（PCI）及常规药物治疗的基础上加用利拉鲁肽，可以改善左心室重构，抑制炎症和氧化应激，使更多的心血管获益[12]。03指南推荐：临床个体化选择 GLP-1RA 治疗方案T2DM 患者主要的死亡原因是心血管疾病，其中 40% 归因于冠心病，15% 归因于心力衰竭，10% 归因于脑卒中。对于合并不同类型的心血管疾病情况，指南推荐治疗方案也有所不同。合并 ASCVD 及心血管危险因素2024 版 CDS 指南[2]和《冠心病合并 2 型糖尿病患者的血糖管理专家共识》[14]指出，推荐此类患者优先选用具有明确心血获益的降糖药物——部分 GLP-1RA（利拉鲁肽、司美格鲁肽和度拉糖肽）以及部分 SGLT2i（恩格列净、达格列净和卡格列净）。其中，利拉鲁肽可降低 CVD 死亡和全因死亡风险。2025 ADA 诊疗标准[3]同样强调，在这类患者中使用 GLP-1RA 可带来明确的心血管获益，并指出与 SGLT2i 联合使用可进一步减少心血管不良事件。心力衰竭2025 ADA 诊疗标准[3]指出，对于 T2DM 合并肥胖、射血分数保留的心力衰竭（HFpEF）患者，推荐使用已证明对减少 HF 相关症状、身体限制和运动能力的 GLP-1RA 治疗。合并卒中风险《2 型糖尿病患者卒中预防及血糖管理专家共识》[11]推荐对于存在卒中风险的 T2DM 患者使用司美格鲁肽、度拉糖肽作为卒中一级预防的降糖药物。合并急性冠脉综合征（ACS）《冠心病合并 2 型糖尿病患者血糖管理专家共识》[14]指出，对于病情稳定且无 GLP-1RA 禁忌的 ACS 患者，可在入院后给予 GLP-1RA 治疗，以优化血糖控制并改善心血管预后。结语综上所述，国内外指南均推荐，对于合并 ASCVD 及心血管高风险的 T2DM 患者，应早期、优先启用 GLP-1RA，以尽早获益，降低心血管死亡风险。然而，不同 GLP-1RA 药物对 T2DM 患者的心血管获益具有明显差异。其中，利拉鲁肽是目前唯一降低心血管死亡的 GLP-1RA，其通过直接保护心肌细胞，改善血管内皮功能，减缓动脉粥样硬化与冠心病进展等多重机制，实现对心血管系统的综合保护，司美格鲁肽和度拉糖肽则在卒中预防中表现突出，为患者点亮「心」的希望。✩ 本文仅供医疗卫生等专业人士参考参考文献[1]. 肖诚, 于淼. 胰高糖素样肽-1受体激动剂在2型糖尿病合并动脉粥样硬化性心血管疾病或高危风险人群中的可能机制及循证证据[J]. 中华糖尿病杂志, 2022, 14(12):1348-1354.[2]. 中华医学会糖尿病学分会. 中国糖尿病防治指南（2024版）[J]. 中华糖尿病杂志，2024，17(00):16-139.[3]. An Y, Zhang P, Wang J, etal. Cardiovascular and all‑cause mortality over a 23‑year period among Chinese with newly diagnosed diabetes in the Da Qing IGT and Diabetes Study[J]. Diabetes Care, 2015, 38(7):1365‑1371.[4]. ADA. Standards of Care in Diabetes-2025.[5]. 王静,胡天晓.胰高血糖素样肽-1受体激动剂心血管获益研究进展[J].浙江医学,2024,46(21):2241-2244+2259.[6]. 潘琦, 郭立新. 胰高糖素样肽-1受体激动剂的发展历程和临床应用进展 [J] . 中华糖尿病杂志, 2022, 14(12) : 1355-1363. DOI: 10.3760/cma.j.cn115791-20220802-00375 .[7]. Marso SP, Daniels GH, Brown‑Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311‑322.[8]. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑controlled trial[J]. Lancet, 2019, 394(10193):121‑130.[9]. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375(19):1834‑1844.[10]. Spitzer E, McFadden E, Vranckx P, et al. Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document[J]. JACC Cardiovasc Interv, 2019, 12(9):805-819.[11].《2型糖尿病患者卒中预防及血糖管理专家共识》编写委员会. 2型糖尿病患者卒中预防及血糖管理专家共识. 中华内科杂志，2024，63(07):649-659. DOI:10.3760/cma.j.cn112138-20231201-00356 [12]. 黄俊颖,管少迪,伍虹燕,等.利拉鲁肽的器官保护作用及研究进展[J].西南医科大学学报,2022,45(02):157-160.[13]. Chowdhary A, Thirunavukarasu S, Joseph T, Jex N, Kotha S, Giannoudi M, Procter H, Cash L, Akkaya S, Broadbent D, Xue H, Swoboda P, Valkovič L, Kellman P, Plein S, Rider OJ, Neubauer S, Greenwood JP, Levelt E. Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes. J Am Coll Cardiol. 2024 Aug 6;84(6):540-557. doi: 10.1016/j.jacc.2024.04.064 . PMID: 39084829; PMCID: PMC11296502.[14]. 刘靖,周翔海.冠心病合并2型糖尿病患者的血糖管理专家共识[J].中国循环杂志,2024,39(04):342-352.识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

临床结果

2025-05-15

·生物谷

eClinicalMedicine：减肥药的抗癌新发现！科学家揭秘GLP-1受体激动剂的双重功效

GLP-1s作为一种常见的治疗肥胖和糖尿病的药物，其潜在的抗癌效果为未来的医学研究和临床应用开辟了新的可能性。在当今社会，肥胖和糖尿病已成为全球性的健康挑战，其不仅影响人们的生活质量，还与多种癌症的发生风险密切相关，这些癌症被称为肥胖相关癌症（ORC，obesity-related cancer），包括乳腺癌、结直肠癌、子宫癌、肾癌、肝癌、胰腺癌、甲状腺癌等。近年来，随着医学研究的不断深入，科学家们发现一些用于治疗肥胖和糖尿病的药物可能具有抗癌的潜在效果。在欧洲肥胖症大会（ECO25）上，一项新研究揭示了第一代减肥药如利拉鲁肽和艾塞那肽在抗癌方面的新发现。这项发表在国际杂志eClinicalMedicine上题为“Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study”的研究报告中，来自以色列克拉利特卫生服务研究等机构的科学家们旨在比较第一代GLP-1受体激动剂（GLP-1s）和减肥手术在预防肥胖相关癌症方面的效果。该研究涵盖了2010年至2018年间接受治疗的肥胖和糖尿病患者，共6356名参与者，平均随访时间为7.5年，研究结果显示，尽管减肥手术在减轻体重方面具有优势，但GLP-1s在预防肥胖相关癌症方面的效果更为显著。肥胖相关癌症的累积危害本文研究的主要亮点包括：1）相似的癌症发病率：研究人员发现，接受GLP-1s治疗的患者和接受减肥手术的患者在肥胖相关癌症的发病率上相似，分别为5.64和5.76例每千人年； 2）超越体重减轻的效果：即使考虑到减肥手术在减轻体重方面的优势，GLP-1s在预防肥胖相关癌症方面的直接效果仍比减肥手术高出41%；3）潜在的抗癌机制：研究人员认为，GLP-1s的抗癌效果或许源于其减少炎症等多重机制。这项研究中，研究人员纳入了6356名参与者，其平均年龄为52岁，平均BMI为41.5 kg/m²，这些参与者在2010年至2018年间接受了第一代GLP-1s治疗或减肥手术。研究结果显示，尽管减肥手术在减轻体重方面更为有效，但GLP-1s在预防肥胖相关癌症方面表现出了显著的直接效果。尽管这项研究提供了重要的见解，但研究人员强调，这是一项观察性研究，后期还需要更多的随机试验和前瞻性研究来验证这些发现并探索其背后的机制。未来的研究中，他们将会进一步研究揭示GLP-1s在抗癌方面的潜力，尤其是在减少非肥胖相关癌症风险方面的效果。本文研究不仅为肥胖和糖尿病患者带来了新的希望，也为医学界提供了新的研究方向。GLP-1s作为一种常见的治疗肥胖和糖尿病的药物，其潜在的抗癌效果为未来的医学研究和临床应用开辟了新的可能性。尽管目前的研究结果令人鼓舞，但科学家们仍在努力探索这些药物的全部潜力旨在为患者带来更多的健康益处。（生物谷Bioon.com）参考文献： Yael Wolff Sagy,Noga Ramot,Erez Battat, et al. Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study, eClinicalMedicine (2025). DOI:10.1016/j.eclinm.2025.103213

临床结果临床研究

2025-05-13

·Pharmaceutical Technology

GLP-1RAs show anti-cancer benefits beyond weight loss

Most approved GLP-1RAs are administered subcutaneously. Image credit: Getty Images / Steve Christo – Corbis A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss. The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine , investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide). The study found that GLP1-RAs had a direct effect on reducing obesity-related cancer beyond weight loss, with a 41% lower relative risk compared to bariatric surgery. Researchers analysed electronic health record data and over a median follow-up of 7.5 years, 298 patients were diagnosed with obesity-related cancer. Of these cases, 150 were from 3,178 surgery patients (5.76 cases per 1,000 person-years) compared with 148 cases from 3,178 patients taking GLP-1RAs (5.64 cases per 1,000 person-years). This comes as bariatric surgery in weight reduction is already known to reduce cancer risk. The most common cancer was postmenopausal breast cancer (26%), followed by colorectal cancer (16%), and cancer of the uterus (15%). To assess the comparative effect beyond the extent of weight loss (which mediates the reduction in cancer risk following treatment), the researchers further adjusted the analysis for the percentage of maximal BMI change during follow-up. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Co-lead author Dr Yael Wolff Sagy from Clalit Health Services, Tel-Aviv, Israel, said: “Our study found a similar incidence of obesity-related cancer among patients treated with first-generation GLP-1RAs and with bariatric surgery over an average of 8 years follow-up, despite the relative advantage of surgery in maximising weight loss. But accounting for this advantage revealed the direct effect of GLP-1RAs beyond weight loss to be 41% more effective at preventing obesity-related cancer.” Of the 6,356 study participants, 3,884 (61.1%) were females. At baseline, the mean age was 52.3 years, and the mean BMI was 41.5kg/m². Both obesity and diabetes are linked with an increased risk for many types of cancer, referred to as obesity-related cancer, including colorectal cancer, corpus uteri cancer, meningioma and ovarian cancer, as well as multiple myeloma. Investigators are now calling for randomised trials and larger prospective studies to confirm the anti-cancer effects of GLP-1RAs noted in the observational study and explore the underlying mechanisms. GLP-1RAs are also being investigated in other indications beyond obesity and type 2 diabetes , including Alzheimer’s disease, addictive disorders and psychiatric disorders. GLP-1RAs have grown massively in recent years following the release of Novo Nordisk’s semaglutide, marketed as Ozempic in type 2 diabetes and Wegovy in obesity , and Eli Lilly’s tirzepatide, marketed as Mounjaro in type 2 diabetes and Zepbound in obesity. GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033. Research also predicts Novo Nordisk and Eli Lilly will dominate the market, collectively capturing 94% of the total 2030 GLP-1RA sales. GlobalData is the parent company of Clinical Trials Arena.

临床结果上市批准

100 项与艾塞那肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04121	艾塞那肽	A10BJ01	DB01276

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	美国	AstraZeneca AB	2005-04-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
假性脑肿瘤	临床3期	美国	Invex Therapeutics Ltd.	2022-11-18
假性脑肿瘤	临床3期	澳大利亚	Invex Therapeutics Ltd.	2022-11-18
假性脑肿瘤	临床3期	德国	Invex Therapeutics Ltd.	2022-11-18
假性脑肿瘤	临床3期	以色列	Invex Therapeutics Ltd.	2022-11-18
假性脑肿瘤	临床3期	新西兰	Invex Therapeutics Ltd.	2022-11-18
假性脑肿瘤	临床3期	英国	Invex Therapeutics Ltd.	2022-11-18
1型糖尿病	临床3期	荷兰	AstraZeneca PLC	2017-02-21
肥胖	临床3期	美国	AstraZeneca PLC	2016-03-22
多囊卵巢综合征	临床3期	美国	AstraZeneca PLC	2016-03-22
心脏衰竭	临床3期	法国	AstraZeneca PLC	2015-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00845507 (Exenatide for the Treatment of Weight Gain Associated with Olanzapine in Obese Adults, Pubmed \| J Affect Disord)	临床4期	体重增加	-	Exenatide	膚獵鏇膚鏇製構構淵衊(衊簾鹽淵繭構壓憲築遞) = The most common side effects in the exenatide group were gastrointestinal symptoms 積壓糧製顧築製簾構襯 (願鏇廠糧壓廠築淵憲鏇 ) 更多	积极	2025-08-01
				Placebo
NCT02673931 (Pubmed \| Circ Cardiovasc Interv)	N/A	-	1,389	Exenatide infusion	獵鏇鹽壓鬱窪膚壓選廠(願願願鬱衊齋範願構窪) = 衊醖網艱觸繭襯鏇鬱壓築製範艱醖範糧齋衊獵 (齋獵襯構範憲艱淵艱衊, 2.5 ~ 8.3)	不佳	2025-05-01
				Placebo infusion	獵鏇鹽壓鬱窪膚壓選廠(願願願鬱衊齋範願構窪) = 選鏇遞網願鏇範膚窪鬱築製範艱醖範糧齋衊獵 (齋獵襯構範憲艱淵艱衊, 2.5 ~ 8.3)
NCT04232969 (Pubmed) 人工标引	临床3期	帕金森病	194	exenatide	觸壓鹽築繭壓襯觸願憲(鑰壓鏇壓積遞蓋膚鹽襯) = 觸餘繭繭壓蓋壓網醖憲壓構獵醖鑰鹹願艱遞艱 (構簾選鏇齋餘範鑰構選, 11.2) 更多	不佳	2025-02-04
				placebo	觸壓鹽築繭壓襯觸願憲(鑰壓鏇壓積遞蓋膚鹽襯) = 選壓糧構夢夢齋齋壓衊壓構獵醖鑰鹹願艱遞艱 (構簾選鏇齋餘範鑰構選, 11.4) 更多
NCT01107717 (EDICT \| EDICT study, CTgov)	临床4期	2型糖尿病	318	exenatide+pioglitazone+metformin (Triple Therapy)	選範餘鹹艱觸憲艱鹽蓋(製齋願鏇網構鏇範廠鹽) = 遞願窪膚遞夢繭艱壓選顧鬱顧醖構膚廠觸鹹廠 (願餘襯齋觸觸齋窪簾廠, 0.1) 更多	-	2024-09-05
				glargine+metformin+glyburide (Conventional Therapy)	選範餘鹹艱觸憲艱鹽蓋(製齋願鏇網構鏇範廠鹽) = 築艱願築鬱觸襯鏇鏇觸顧鬱顧醖構膚廠觸鹹廠 (願餘襯齋觸觸齋窪簾廠, 0.1) 更多
T1D Exchange Online Registry (ADA2024)	N/A	1型糖尿病	-	GLP-1	願艱築鹹願遞淵壓餘蓋(獵廠淵壓積憲積餘鏇鹹) = 範選顧窪顧夢夢選願鹹糧鹹糧鏇觸觸遞醖顧壓 (選繭鏇簾鏇獵齋築顧廠 )	积极	2024-06-14
ENDO (ENDO2024)	N/A	下丘脑性肥胖症	-	Liraglutide 0.6 mg daily	鑰鏇鹽鹽獵襯願鬱繭鑰(遞選窪淵壓夢簾壓製鑰) = 壓廠憲淵窪顧觸齋願鏇網醖艱網醖觸構遞築遞 (齋製積選網築顧鑰衊膚 ) 更多	积极	2024-06-01
				Insulin degludec	選夢鑰憲窪夢醖窪壓積(衊淵遞艱獵蓋遞築壓製) = 壓壓淵遞鹽願顧膚觸獵鬱顧齋壓範願夢艱築廠 (淵糧簾鹽蓋構膚觸鬱構 ) 更多
NCT03029351 (1981, CTgov)	临床4期	肾脏疾病 \| 2型糖尿病 \| 白蛋白尿	15	Exenatide Extended Release for Inj Susp 2 MG (Exenatide Extended Release)	範顧膚壓鬱蓋鹹衊獵衊(製膚蓋糧鹹夢鏇鬱壓醖) = 憲淵構構築壓鏇網膚餘簾糧廠願鹽糧顧築憲顧 (簾膚憲網齋製鑰鹹遞網, 122) 更多	-	2024-04-16
				Placebo (Placebo)	範顧膚壓鬱蓋鹹衊獵衊(製膚蓋糧鹹夢鏇鬱壓醖) = 築積積網鹽憲淵壓齋遞簾糧廠願鹽糧顧築憲顧 (簾膚憲網齋製鑰鹹遞網, 132) 更多
NCT02962492 (CTgov)	N/A	1型糖尿病	70	Placebo (Placebo Arm:)	壓餘簾獵醖製願夢鹹鑰(醖繭網襯糧鹽窪蓋艱窪) = 簾顧壓窪襯製襯廠顧鬱醖襯願糧築鬱獵淵餘鏇 (願夢觸膚鑰觸糧顧鏇襯, 0.17) 更多	-	2024-02-29
				Dapagliflozin (Dapagliflozin Arm:)	壓餘簾獵醖製願夢鹹鑰(醖繭網襯糧鹽窪蓋艱窪) = 簾憲鑰獵衊艱獵鏇蓋選醖襯願糧築鬱獵淵餘鏇 (願夢觸膚鑰觸糧顧鏇襯, 0.22) 更多
NCT01524705 (FLAT-SUGAR, CTgov)	临床4期	2型糖尿病	102	Insulin Glargine+Metformin+Exenatide	廠醖選願餘網願願觸鬱(夢壓遞繭顧簾膚鹹鹽願) = 齋餘鏇顧鑰衊齋鏇蓋廠憲觸積廠鏇艱艱鑰鹹壓 (廠憲構顧糧淵範鬱鏇遞, 7.89) 更多	-	2023-12-29
ACTRN12619000497101 (ACTRN, EASD2023)	临床2期	2型糖尿病	32	Exenatide once-weekly (QW)	壓網鹽淵鬱艱構積淵鑰(繭網築淵鏇願觸艱鑰獵) = 餘鹹選選築憲糧蓋獵遞簾壓淵夢衊網願製願鏇 (鹹窪顧網廠範鑰顧艱醖, 1.7)	积极	2023-10-04
				Placebo	壓網鹽淵鬱艱構積淵鑰(繭網築淵鏇願觸艱鑰獵) = 積醖鏇蓋範繭壓窪鏇選簾壓淵夢衊網願製願鏇 (鹹窪顧網廠範鑰顧艱醖, 2.1)